Status:

UNKNOWN

High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis

Lead Sponsor:

Università Politecnica delle Marche

Conditions:

Scleroderma, Diffuse

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

PHASE3

Brief Summary

* Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder characterized by fibrosis of the skin and visceral organs that alters every aspect of an individual life * Although som...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of early diffuse scleroderma
  • ability to give an informed consent
  • use of an acceptable method of birth control (if women in childbearing age). Pregnancy will be ruled out before study beginning.

Exclusion

  • connective tissue diseases or other autoimmune diseases other than SSc;
  • history of intolerance to the study drugs;
  • severe cardiac failure (NYHA \>=3 or left ventricular ejection fraction \<40%), recent (\<6 months) history of myocardial infarction; symptomatic ischemic myocardial disease, ventricular tachyarrhythmia, atrial fibrillation;
  • resting PaO2 \<60mm/hg
  • creatinine clearance below 90ml/h
  • severe hepatic failure
  • bronchial asthma h. hemorrhagic diathesis i. pregnancy or lactation

Key Trial Info

Start Date :

January 1 2007

Trial Type :

INTERVENTIONAL

End Date :

February 1 2009

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT00428883

Start Date

January 1 2007

End Date

February 1 2009

Last Update

January 30 2007

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Università politecnica delle marche

Ancona, Italy, 60020

2

Università di Firenze

Florence, Italy

3

Università de L'Aquila

L’Aquila, Italy

4

Seconda Università di Napoli

Napoli, Italy

High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis | DecenTrialz